That's fiddly to calculate for COVID ARDS as waves of COVID infections are difficult to guess. I guess just treat it as growth potential.
As for Non-covid ARDS (the more stable treatment opportunity), assuming pricing is the same as US (which is probably optimistic) royalty revenue for top 5 European countries by population would be about AUD $600M. With less optimistic pricing maybe add AUD $400M royalty revenue.
I've assumed 20% of the moderate and severe cases are treated.
I guess a deal for Europe would most likely be for all of Europe rather than just the top 5 countries.
Depending on P/E used would add $17.55 to $55.28 to the MSB share price.
MSB - Most exciting 6 months, page-402
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.050(4.65%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.13 | $1.07 | $5.964M | 5.444M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 25000 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 176236 | 7 |
View Market Depth
| Last trade - 16.10pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.12 |
Change
0.050 ( 4.69 %) |
||||
| Open | High | Low | Volume | ||
| $1.09 | $1.13 | $1.07 | 829227 | ||
| Last updated 15.59pm 21/05/2024 ? | |||||
| MSB (ASX) Chart |